Science and Research

A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab Maintenance Folllowing First-Line Platinum Based Chemotherapy in Patients with Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC)

A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients with Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC).

Study details
Study-ID: NCT02564380, 2015-001123-22
Study-ID: NCT02564380, 2015-001123-22
DZL Disease Area: LC
DZL Disease Area: LC
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL Investigator Initiated Trial
DZL Role: DZL Investigator Initiated Trial
Funding: Externally - industry
Funding: Externally - industry
DZL Participating Sites: ARCN
DZL Participating Sites: ARCN
Start Date: 19.01.2016
Completion Date: 23.11.2020
Status: Terminated
Status: Terminated
DZL Investigator Initiated Trial
Link to Study


close
chevron-down

Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.